National Institute of Allergy, 2014-11-17: Registry record for a phase 1 oxfendazole trial sponsored by NIAID: phase 1, 70 healthy volunteers, started 17 November 2014, completed, with results posted. It is the human-registry counterpart of FBB-23.
NCT02234570 – Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole – Phase 1 – COMPLETED – Enrollment 70 – Start 2014-11-17 – Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID) – Condition: Neurocysticercosis
National Institute of Allergy, 2014-11-17: Registry record for a phase 1 oxfendazole trial sponsored by NIAID: phase 1, 70 healthy volunteers, started 17 November 2014, completed, with results posted. It is the human-registry counterpart of FBB-23. Record field (registry entry), transcribed from the ClinicalTrials.gov API v2 record on 2026-11-19; fields joined with ' – '. Registered trial with results; no fenbendazole trial exists in the same registry (see Run Notes). Study type: interventional phase 1. Registry entry; results posted. Counterpart of FBB-23.
